ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

MVA-BN smallpox vaccine

Also written as “IMVAMUNE”, “IMVAMUNE (MVA-BN)” and “IMVAMUNE®”.

Its studies are mostly in Smallpox · Mpox, Monkeypox · Dermatitis, Atopic · HIV Infections, led by 3 companies.

Drug pageMVA-BN smallpox vaccine: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 5, 201816 company-led studies, 2 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bavarian Nordicits history only142 open or runningphase 4since Mar 5, 2018Sep 11, 2005Nov 30, 2026phase 2 · NCT07199569
Johnson & Johnsonits history only10 open or runningearly phase 1since Apr 1, 2019Apr 1, 2019none ahead
Sanofi10 open or runningphase 2since Apr 25, 2007Apr 25, 2007none ahead

Also a collaborator on its studies: ICON.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 25, 2007First study: phase 2 study in SmallpoxFirst studyNCT00466245 · 590 enrolled

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox, ”NCIt, by rule

Studies

The one study Sanofi leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00466245Smallpox2CompletedJun 2006590

How it is read

Names in the registry

  • “IMVAMUNE”, 5 entries
  • “IMVAMUNE (MVA-BN)”, 4 entries
  • “IMVAMUNE®”, 3 entries
  • “MVA-BN”, 2 entries
  • “MVA-BN (Quail)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.